What semaglutide is and why it's used for weight loss
Semaglutide is a medication belonging to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed and approved by the FDA for the treatment of Type 2 diabetes, it has since gained widespread attention for its effectiveness in chronic weight management. The medication is marketed under several brand names depending on its specific formulation and indication: Ozempic and Rybelsus are primarily used for diabetes, while Wegovy is specifically approved for weight loss. Although these products contain the same active ingredient, they differ in dosage strengths and official indications.
Semaglutide works by mimicking a natural hormone released in the gut after eating. This hormone helps regulate blood sugar and appetite by acting on areas of the brain that control feeding behavior. Semaglutide slows down gastric emptying, which keeps food in the stomach longer, and promotes a feeling of fullness (satiety). By reducing appetite and decreasing the desire to eat, the medication helps individuals consume fewer calories.
Semaglutide is not a standalone solution for weight loss. The FDA requires it to be used as an adjunct to a reduced-calorie diet and increased physical activity. The medication is designed to support these lifestyle changes by making it easier to adhere to a lower-calorie intake, rather than replacing the need for healthy eating habits or exercise.
Clinical trial results: how much weight people lost
Clinical trials, particularly the STEP (Semaglutide Treatment Effect in People with obesity) series, have provided robust data on the effectiveness of semaglutide. In the primary STEP 1 trial, which included adults without diabetes, participants who received a 2.4 mg weekly injection of semaglutide lost an average of 14.9% of their baseline body weight over 68 weeks. By comparison, those in the placebo group lost an average of 2.4%. Nearly 86% of participants taking semaglutide achieved at least a 5% reduction in body weight, a threshold often associated with significant health improvements, compared to about 31% in the placebo group.
Results vary for different populations. In the STEP 2 trial, which involved adults with Type 2 diabetes, the average weight loss was slightly lower at 9.6% over the same 68-week period. This is still substantially greater than the 3.4% loss seen in the diabetic placebo group. When semaglutide was paired with intensive behavioral therapy-including structured diet planning and multiple visits with a dietitian-the average weight loss increased to 16.0% in the STEP 3 trial.
Comparative data also highlights its potency relative to older medications. In the STEP 8 trial, semaglutide resulted in an average weight loss of 15.8%, significantly outperforming liraglutide (another GLP-1 drug), which yielded a 6.4% average loss. While these results demonstrate strong efficacy on average, individual outcomes vary based on adherence to lifestyle changes, baseline health, and other factors.
How semaglutide compares to other weight-loss medications
When compared to earlier FDA-approved weight-loss medications, semaglutide demonstrates superior average weight loss outcomes. Older medications such as orlistat typically result in approximately 8% body weight loss over a year. Phentermine (an appetite suppressant) and the combination of naltrexone-bupropion generally yield averages between 5% and 9%. Liraglutide, the previous GLP-1 option for weight loss, produces about 8% average loss. Semaglutide's average of 14-16% represents a marked improvement over these earlier treatments.
Semaglutide also offers convenience advantages. Prior to its approval, liraglutide required daily subcutaneous injections. Semaglutide is the first once-weekly injectable medication approved for chronic weight management, which may improve adherence for some patients.
The landscape of weight-loss medications is evolving. Tirzepatide, a newer medication that targets both GLP-1 and GIP receptors, has shown even greater average weight loss (approximately 20%) in head-to-head comparisons. An oral tablet formulation of semaglutide was recently approved for weight management, offering an alternative for individuals who prefer not to use injections. While oral semaglutide showed comparable results to the injectable version in trials, individual preferences and physiological responses may vary.
Understanding semaglutide for weight loss
When weight-loss results typically appear
Weight loss with semaglutide is a gradual process rather than a rapid drop. Before reaching the full therapeutic dose, patients undergo a titration period that lasts approximately 16 to 20 weeks. The medication starts at a low dose (0.25 mg weekly) and is increased every four weeks through intermediate doses (0.5 mg, 1 mg, 1.7 mg) until reaching the maintenance dose of 2.4 mg. This gradual escalation is designed to help the body adjust and minimize gastrointestinal side effects.
Most people begin to see weight loss during this titration phase, but the majority of the effect occurs while on the maintenance dose. The average figures cited in clinical trials (14-16% loss) reflect results measured at Week 68, which is roughly 16 months from the start of treatment. This timeline includes both the initial titration period and over a year of stable dosing.
Because the effects are cumulative, patients should not expect dramatic changes in the first few weeks. The expectation should be a steady, progressive decline in weight over many months. Semaglutide is intended for long-term use rather than as a short-term intervention, and consistent adherence to both the medication schedule and lifestyle modifications is necessary to achieve the results seen in clinical trials.
Common side effects and how to manage them
The most common side effects associated with semaglutide are gastrointestinal in nature. These include nausea, diarrhea, vomiting, constipation, and abdominal pain. These symptoms are often most prominent when starting the medication or when increasing the dose. For most users, these side effects are mild to moderate and tend to decrease in intensity over time as the body adjusts to the treatment.
To help manage these side effects, patients are often advised to eat smaller meals, avoid high-fat or spicy foods, and stay well-hydrated. Some individuals may find that delaying a dose increase can reduce severity. For a subset of users, gastrointestinal symptoms can be severe enough to interfere with daily activities or lead to discontinuation. Data from clinical trials indicates that while the majority of participants tolerate the medication well, approximately 4-18% discontinue treatment due to side effects or lack of efficacy.
Beyond common gastrointestinal issues, there are serious but rarer risks. These include acute pancreatitis and gallbladder problems. There is also a risk of kidney injury, which can occur secondary to dehydration from severe vomiting or diarrhea. Semaglutide carries an FDA boxed warning regarding thyroid C-cell tumors, based on findings in rodent studies. While it is not known if this risk applies to humans, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use this medication.
Who should and should not use semaglutide
Semaglutide (Wegovy) is FDA-approved for specific populations. It is indicated for adults with a body mass index (BMI) of 30 kg/m² or higher (obesity), or those with a BMI of 27 kg/m² or higher (overweight) who have at least one weight-related medical condition, such as hypertension, Type 2 diabetes, or dyslipidemia. It is also approved for adolescents aged 12 years and older with obesity.
There are strict contraindications for its use. Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must not take semaglutide due to the risk of thyroid tumors. Those with a known serious hypersensitivity reaction to semaglutide should also avoid it.
Certain medical conditions require careful consideration and monitoring. Patients with a history of pancreatitis, severe gastrointestinal diseases like gastroparesis, or renal impairment should use the medication with caution. Individuals with Type 2 diabetes and a history of diabetic retinopathy may experience a temporary worsening of their eye condition, particularly if blood sugar levels improve rapidly. Because of these risks, a thorough medical evaluation by a healthcare provider is essential to determine if semaglutide is safe and appropriate for an individual's specific health profile.
What happens when you stop taking semaglutide
The effects of semaglutide on appetite suppression and weight loss are not permanent. Clinical evidence demonstrates that weight regain is common once the medication is discontinued. In the STEP 4 withdrawal trial, participants who had lost weight while taking semaglutide were randomized to either continue the drug or switch to a placebo. Over the next 48 weeks, those who switched to placebo regained an average of 6.9% of their baseline body weight. Those who continued taking semaglutide maintained their loss and achieved additional weight reduction.
Broader analyses, including meta-analyses of GLP-1 receptor agonists, confirm that most individuals regain a substantial portion of their lost weight within one to two years after stopping treatment, often returning toward their baseline weight. This pattern suggests that obesity is a chronic condition requiring long-term management for many people.
Lifestyle changes such as diet and exercise remain critical components of health, but they are often insufficient on their own to maintain the weight loss achieved with medication after discontinuation. Rather than viewing weight regain as a personal failure, it is helpful to understand it as the expected physiological response when the medication's effects wear off. Semaglutide is generally intended for long-term use under medical supervision rather than as a temporary fix.
Cost, insurance, and how to get semaglutide
Accessing semaglutide for weight loss involves navigating significant cost and insurance barriers. The wholesale acquisition cost for Wegovy (the FDA-approved formulation for weight loss) is approximately $1,300 to $1,600 per month. This high price point makes the medication inaccessible to many patients without robust coverage.
Insurance coverage varies widely. Under federal law, Medicare Part D does not cover medications primarily used for weight loss. Many commercial insurance plans may cover Wegovy, but they often require prior authorization and strict adherence to BMI criteria. Medicaid coverage differs by state, with some states offering limited coverage for FDA-approved weight-loss medications. Manufacturer savings programs are available for eligible patients with commercial insurance to help offset out-of-pocket costs.
To obtain semaglutide, a patient requires a prescription from a qualified healthcare provider who can evaluate their medical history and determine appropriateness. Some individuals seek alternative access through off-label prescriptions of Ozempic (the diabetes formulation), telehealth services specializing in weight management, or compounded versions of the drug. Compounded medications may not be regulated by the FDA, raising safety concerns about purity and dosage accuracy. Patients should prioritize working with licensed healthcare providers to ensure safe, monitored, and legally compliant treatment.
Semaglutide is a GLP-1 receptor agonist approved for chronic weight management (Wegovy) and for Type 2 diabetes under other brand names. It mimics a gut hormone, slows gastric emptying, and reduces appetite and the desire to eat, but it is intended as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone solution. In clinical trials, average weight loss was about 14-16% over 68 weeks in adults without diabetes, with lower average loss in people with Type 2 diabetes and greater loss when combined with intensive behavioral therapy. Individual results vary. Semaglutide is a once-weekly injectable that generally produces gradual weight loss over months during and after a titration period, and it is intended for long-term use. It has shown superior average weight loss to older weight-loss medications; newer tirzepatide has shown greater average loss, and an oral semaglutide formulation has been approved for weight management.
The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and abdominal pain. They are often most prominent when starting the medication or increasing the dose and are usually mild to moderate, tending to decrease over time, though some people discontinue treatment. Smaller meals, avoiding high-fat or spicy foods, and staying hydrated may help. Serious but rarer risks include acute pancreatitis, gallbladder problems, and kidney injury secondary to dehydration from severe vomiting or diarrhea. Semaglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies, although it is not known whether this risk applies to humans. It must not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2, or by those with a known serious hypersensitivity to semaglutide. Caution and monitoring are needed with a history of pancreatitis, severe gastrointestinal diseases such as gastroparesis, renal impairment, or diabetic retinopathy in people with Type 2 diabetes. It is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and for adolescents aged 12 and older with obesity.
Weight regain is common after stopping semaglutide. In a withdrawal trial, participants who switched to placebo regained an average of 6.9% of their baseline body weight over 48 weeks, while those who continued treatment maintained or increased their loss; broader analyses show most people regain a substantial portion of lost weight within one to two years, often returning toward baseline. Obesity is often a chronic condition requiring long-term management. Cost and insurance are major barriers: Wegovy's wholesale acquisition cost is roughly $1,300 to $1,600 per month, Medicare Part D does not cover medications primarily used for weight loss, commercial coverage often requires prior authorization and strict BMI criteria, Medicaid coverage varies by state, and manufacturer savings programs may help eligible patients. Compounded versions may not be FDA-regulated, raising concerns about purity and dosage accuracy, so patients should work with licensed healthcare providers for safe, monitored treatment.
Source organization: New England Journal of Medicine
Source organization: Diabetes, Obesity and Metabolism
Questions & comments
Can I start semaglutide if I only have a BMI of 26 and no other health issue?
Semaglutide is not FDA-approved for that BMI range - the drug is indicated only for BMI ≥ 30 or BMI ≥ 27 with a weight-related medical condition. A prescriber could still prescribe it off-label, but most insurance plans will not cover the medication in that circumstance.
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.